Oncology · Gynecologic Oncology
The facts most likely to be tested
Postmenopausal bleeding is the classic presentation and mandates an endometrial biopsy to rule out malignancy.
Unopposed estrogen exposure, such as in obesity, nulliparity, or PCOS, is the primary risk factor for Type I endometrioid adenocarcinoma.
Lynch syndrome (HNPCC) is a major genetic risk factor, necessitating screening for microsatellite instability (MSI) in patients with a strong family history.
Transvaginal ultrasound (TVUS) is the initial imaging modality, where an endometrial stripe thickness >4 mm in a postmenopausal patient warrants tissue sampling.
Endometrial biopsy (EMB) is the gold standard diagnostic procedure, providing definitive histopathologic confirmation.
Total hysterectomy with bilateral salpingo-oophorectomy (TH/BSO) is the primary treatment for the majority of patients with localized disease.
Type II endometrial cancer, such as serous or clear cell carcinoma, is typically estrogen-independent, occurs in older women, and carries a significantly worse prognosis.
Vignette unlocked
A 62-year-old G0P0 female presents to the clinic complaining of intermittent vaginal spotting for the past three weeks. She went through menopause at age 53 and has no history of hormone replacement therapy. Her medical history is significant for obesity (BMI 38 kg/m²) and hypertension. On physical examination, the uterus is non-tender and normal in size, and the cervix appears healthy. A transvaginal ultrasound reveals an endometrial stripe thickness of 8 mm.
What is the most appropriate next step in the management of this patient?
Endometrial biopsy
The patient presents with postmenopausal bleeding and an endometrial stripe >4 mm, which requires an endometrial biopsy to rule out endometrial cancer as per the diagnostic algorithm.
Full handout
High yield triage
Etiology / Epidemiology
Most common gynecologic malignancy; driven by unopposed estrogen. Risk factors include obesity, nulliparity, and Lynch syndrome.
Clinical Manifestations
Classic presentation is postmenopausal bleeding. Any bleeding in a postmenopausal patient is cancer until proven otherwise.
Diagnosis
Endometrial biopsy is the gold standard. Endometrial stripe >4 mm on transvaginal ultrasound warrants biopsy.
Treatment
Total hysterectomy with bilateral salpingo-oophorectomy is the primary treatment. Do not perform biopsy if pregnant.
Prognosis
Generally favorable due to early detection. Stage I disease has a 5-year survival rate of >90%.
Full handout
Epidemiology & Etiology
Primarily affects postmenopausal women (mean age 60). Major risk factors include obesity (peripheral conversion of androgens to estrone), tamoxifen use, early menarche, and late menopause. Lynch syndrome (HNPCC) significantly increases lifetime risk via mismatch repair gene mutations.
Pertinent Anatomy
The endometrium lines the uterine cavity. Spread typically occurs via direct extension into the myometrium or lymphatic dissemination to pelvic and para-aortic nodes.
Pathophysiology
Type I (estrogen-dependent) arises from atypical endometrial hyperplasia. Type II (estrogen-independent) is typically high-grade, serous, or clear cell histology, often occurring in older, non-obese women with an atrophic endometrium.
Clinical Manifestations
Postmenopausal bleeding is the hallmark symptom. Red flag: Any vaginal bleeding in a postmenopausal patient requires immediate evaluation. Patients may present with hematometra or pelvic pain in advanced stages.
Diagnosis
Endometrial biopsy (office-based) is the gold standard for tissue diagnosis. Transvaginal ultrasound is the initial screening tool; an endometrial stripe >4 mm in a postmenopausal patient is the threshold for biopsy. If biopsy is non-diagnostic, hysteroscopy with D&C is required.
Treatment
Total hysterectomy with bilateral salpingo-oophorectomy (TH-BSO) is the definitive treatment. Adjuvant radiation or chemotherapy is reserved for high-risk or advanced stages. Progestin therapy may be considered for fertility-sparing in highly selected, low-grade cases.
Prognosis
Prognosis is determined by FIGO staging and histologic grade. Stage I is confined to the uterus, while Stage IV involves distant metastasis or bladder/bowel mucosa. Recurrence monitoring involves serial pelvic exams.
Differential Diagnosis
Atrophic vaginitis: thin, pale mucosa with friability
Endometrial polyps: often asymptomatic or intermenstrual bleeding
Endometrial hyperplasia: precursor lesion without invasion
Cervical cancer: visible lesion on cervix
Uterine leiomyoma: typically presents with heavy, regular menses